Literature DB >> 31211875

Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study.

Anna Baiges1, Fanny Turon1, Macarena Simón-Talero2, Stephanie Tasayco2, Javier Bueno3, Kamal Zekrini4, Aurélie Plessier4, Stéphanie Franchi-Abella5, Florent Guerin5, Amar Mukund6, C E Eapen7, Ashish Goel7, Nidugala Keshava Shyamkumar8, Sandra Coenen9, Andrea De Gottardi10, Avik Majumdar11, Simona Onali11, Akash Shukla12, Flair José Carrilho13, Lucas Nacif13, Massimo Primignani14, Giulia Tosetti14, Vicenzo La Mura14,15, Frederik Nevens16, Peter Witters16, Dhiraj Tripathi17, Luis Tellez18, Javier Martínez18, Carmen Álvarez-Navascués19, Miguel López Fraile López19, Bogdan Procopet20, Fabio Piscaglia21, Barbara de Koning22, Elba Llop23, Mario Romero-Cristobal24, Eric Tjwa25, Alberto Monescillo-Francia26, Marco Senzolo27, Mercedes Perez-LaFuente28, Antonio Segarra28, Shiv Kumar Sarin29, Virginia Hernández-Gea1, David Patch11, Wim Laleman15, Hermien Hartog9, Dominique Valla4, Joan Genescà2, Juan Carlos García-Pagán1.   

Abstract

Congenital extrahepatic portosystemic shunt (CEPS) or Abernethy malformation is a rare condition in which splanchnic venous blood bypasses the liver draining directly into systemic circulation through a congenital shunt. Patients may develop hepatic encephalopathy (HE), pulmonary hypertension (PaHT), or liver tumors, among other complications. However, the actual incidence of such complications is unknown, mainly because of the lack of a protocolized approach to these patients. This study characterizes the clinical manifestations and outcome of a large cohort of CEPS patients with the aim of proposing a guide for their management. This is an observational, multicenter, international study. Sixty-six patients were included; median age at the end of follow-up was 30 years. Nineteen patients (28%) presented HE. Ten-, 20-, and 30-year HE incidence rates were 13%, 24%, and 28%, respectively. No clinical factors predicted HE. Twenty-five patients had benign nodular lesions. Ten patients developed adenomas (median age, 18 years), and another 8 developed HCC (median age, 39 years). Of 10 patients with dyspnea, PaHT was diagnosed in 8 and hepatopulmonary syndrome in 2. Pulmonary complications were only screened for in 19 asymptomatic patients, and PaHT was identified in 2. Six patients underwent liver transplantation for hepatocellular carcinoma or adenoma. Shunt closure was performed in 15 patients with improvement/stability/cure of CEPS manifestations.
Conclusion: CEPS patients may develop severe complications. Screening for asymptomatic complications and close surveillance is needed. Shunt closure should be considered both as a therapeutic and prophylactic approach.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2019        PMID: 31211875     DOI: 10.1002/hep.30817

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

2.  Involution of Hepatocellular Neoplasm after Embolization of a Portosystemic Vascular Shunt in an Adult with Abernethy Type II Malformation.

Authors:  Natalia Paez Arango; Yujiro Nishioka; Jenilette Velasco; Armeen Mahvash; Reza J Mehran; Lan S Wang; Melissa W Taggart; Jean Nicolas Vauthey; Bruno C Odisio
Journal:  J Vasc Interv Radiol       Date:  2021-09       Impact factor: 3.682

3.  Caution for living donor liver transplantation with congenital portosystemic shunt: a case report.

Authors:  Yoshihiro Nagao; Katsuya Toshida; Akinari Morinaga; Takahiro Tomiyama; Yukiko Kosai; Tomonari Shimagaki; Takahiro Tomino; Huanlin Wang; Takeshi Kurihara; Takeo Toshima; Kazutoyo Morita; Shinji Itoh; Noboru Harada; Tomoharu Yoshizumi
Journal:  Surg Case Rep       Date:  2022-10-06

4.  Clinical characteristics and therapeutic outcomes of pulmonary arterial hypertension secondary to congenital portosystemic shunts.

Authors:  Jinjin Wu; Yi Lu; Wenzhuo Zhao; Jie Shen; Fen Li; Hao Zhang; Qimin Chen; Lijun Fu
Journal:  Eur J Pediatr       Date:  2020-10-03       Impact factor: 3.183

5.  An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration.

Authors:  Hironori Tanaka; Yoshihito Saijo; Tetsu Tomonari; Takahiro Tanaka; Tatsuya Taniguchi; Shusuke Yagi; Koichi Okamoto; Hiroshi Miyamoto; Masahiro Sogabe; Yasushi Sato; Naoki Muguruma; Koichi Tsuneyama; Masataka Sata; Tetsuji Takayama
Journal:  Intern Med       Date:  2021-01-15       Impact factor: 1.271

Review 6.  Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting.

Authors:  Federica Vernuccio; Domenico Salvatore Gagliano; Roberto Cannella; Ahmed Ba-Ssalamah; An Tang; Giuseppe Brancatelli
Journal:  Insights Imaging       Date:  2021-01-12

7.  Case Report: Membranoproliferative Glomerulonephritis, a Rare Clinical Manifestation of Abernethy Malformation Type II.

Authors:  Xue He; Yueling Zhu; Haidong Fu; Chunyue Feng; Zhixia Liu; Weizhong Gu; Yanyan Jin; Binbin Yang; Huijun Shen
Journal:  Front Pediatr       Date:  2021-03-17       Impact factor: 3.418

8.  Congenital extrahepatic portocaval malformation: Rare but potentially treatable cause of pulmonary hypertension.

Authors:  Prashant Bobhate; Sandeep Garg; Anuj Sharma; Diptiman Roy; Abhijeet Raut; Ravindra Pawar; Tanuja Karande; Snehal Kulkarni
Journal:  Indian Heart J       Date:  2020-12-30

9.  Efficacy and Safety of Surgical Ligation versus Endovascular Embolization for Type II Congenital Extrahepatic Portosystemic Shunt.

Authors:  Jinlong Zhang; Weidong Duan; Zhuting Fang; Maoqiang Wang; Li Cui; Yanhua Bai; Xiaohui Li; Qicong Du; Mengqiu Shen; Feng Duan
Journal:  Biomed Res Int       Date:  2021-05-31       Impact factor: 3.411

Review 10.  Abernethy syndrome in Slovenian children: Five case reports and review of literature.

Authors:  Jerneja Peček; Petja Fister; Matjaž Homan
Journal:  World J Gastroenterol       Date:  2020-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.